Quantcast

Roche Diagnostics launches the cobas(R) 8000 modular analyzer series in Canada at BC Biomedical Laboratories

May 12, 2011

Vancouver site represents first North American installation of new high
volume analyz
er.

LAVAL, QC, May 12 /PRNewswire/ – Roche Diagnostics Canada is pleased to
announce the launch of the cobas® 8000 modular analyzer series. In
parallel with the launch of this latest member of Roche’s “cobas”
family of laboratory testing platforms, Roche Diagnostics Canada has
completed the first North American installation of the cobas 8000
system at BC Biomedical Laboratories.

The cobas 8000 modular analyzer series, which fully integrates both
clinical chemistry and immunoassay testing, is comprised of the cobas c
702, cobas c 701 and cobas c 502 modules for clinical chemistry as well
as the cobas e 602 module for immunoassay testing. It is designed to
meet the needs of high volume laboratories that perform between 3 to 15
million tests per year and delivers high quality results fast and
efficiently from a single patient sample.

“At BC Bio, we are committed to providing diagnostic health care of the
highest quality,” said Brenda Jackson, Clinical Manager of Chemistry,
Hematology and Cardiac Services at BC Biomedical Laboratories. “The
cobas 8000 analyzer helps us deliver on our mission. It combines
high-throughput performance with the analytical precision and
sensitivity we require for our physicians and patients.”

BC Biomedical Laboratories Ltd. is the largest physician-owned and
operated laboratory in British Columbia. Each year, more than 1.9
million patients visit one of BC Biomedical’s 45 Patient Service
Centres throughout the Lower Mainland, which translates into a workload
of approximately 10 million tests. “With the cobas 8000 we are able to
processes over 60% of our total patient workload in a fraction of the
time we used to take – a tremendous increase in productivity that
allows us to refocus our staff on new value added tasks across the
laboratory.”

“What distinguishes the cobas 8000 is that it delivers true high-volume
performance with a comprehensive testing menu that offers an
unprecedented level of workload consolidation. For today’s busy
laboratories, this means greatly enhanced levels in testing efficiency
and enhanced medical value.” Added Christopher Parker, President and
General Manager of Roche Diagnostics in Canada.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in pharmaceuticals
and diagnostics. Roche is the world’s largest biotech company with
truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro
diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes
management. Roche’s personalised healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the
health, quality of life and survival of patients. In 2010, Roche had
over 80’000 employees worldwide and invested over 9 billion Swiss
francs in R&D. The Group posted sales of 47.5 billion Swiss francs.
Genentech, United States, is a wholly owned member of the Roche Group.
Roche has a majority stake in Chugai Pharmaceutical, Japan. For more
information: www.roche.com.

About BC Biomedical Laboratories

BC Biomedical Laboratories Ltd. is the community laboratory practice of
Dr. C.J. Coady Associates and is the largest physician-owned and
operated laboratory in British Columbia. Each year, more than 1.9
million patients visit one of our 45 Patient Service Centres throughout
the Lower Mainland. For 50 years, our medical diagnostic services have
been an integral part of the BC health care system. Our community
laboratory helps to diagnose, manage and cure illness by providing
laboratory services. Above all, we are dedicated to providing
diagnostic health care of the highest quality. We support and promote
the well-being of our employees, our patients, the physicians we serve,
and our community.

All trademarks used or mentioned in this release are protected by law.

SOURCE Roche Diagnostics


Source: newswire



comments powered by Disqus